US Military contributions to the global response to pandemic Chikungunya

Vaccine

Volumn 30, Issue 47, 2012, Pages 6713-6720

  Hoke, Charles H ^a   Pace Templeton, Judy ^a   Pittman, Phillip ^b   Malinoski, Frank J ^b   Gibbs, Paul ^b   Ulderich, Tracy ^c   Mathers, Michelle ^a   Fogtman, Beverly ^b   Glass, Pamela ^b   Vaughn, David W ^d  

^a US Army Medical Materiel Development Activity (USAMMDA)   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

^d Mil Infect Dis Research Program   (United States)

Author keywords

Chikungunya; Manufacturing; Pandemic; US Military; Vaccine

Indexed keywords

CHIKUNGUNYA VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARMY; ARTICLE; CHIKUNGUNYA; DRUG MANUFACTURE; DRUG POTENCY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; PANDEMIC; PRIORITY JOURNAL; UNITED STATES; VACCINE PRODUCTION;

ALPHAVIRUS INFECTIONS; CLINICAL TRIALS AS TOPIC; EMERGENCIES; HUMANS; INTERNATIONAL COOPERATION; MILITARY PERSONNEL; PANDEMICS; TECHNOLOGY TRANSFER; UNITED STATES; VACCINES, ATTENUATED; VIRAL VACCINES; WORLD HEALTH;

EID: 84867477389     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.025     Document Type: Article

References (39)

1. CDC arbovirus catalog. [accessed 20.04.12]. http://wwwn.cdc.gov/arbocat/catalog-listing.asp%3FVirusID=108%26SI=2.
2. Diallo M., Thonnon J., Traore-Lamizana M., Fontenille D. Vectors of Chikungunya virus in Senegal: current data and transmission cycles. Am J Trop Med Hyg 1999, 60(February (2)):281-286.
3. Sissoko D., Malvy D., Ezzedine K., Renault P., Moscetti F., Ledrans M., et al. Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic manifestations and associated factors over a 15-month period. PLoS Negl Trop Dis 2009, 3:e389.
4. Halstead S.B. Chikungunya. Textbook of pediatric infectious diseases 2006, 2314-2316. W.B. Saunders, Philadelphia, [chapter 187D]. 6th ed. R.D. Feigin, J.D. Cherry (Eds.).
5. Laras K., Sukri N.C., Larasati R.P., Bangs M.J., Kosim R., Djauzi, et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg 2005, 99:128-141.
6. Burke D.S., Nisalak A., Nimmannitya S. Disappearance of Chikungunya virus from Bangkok. Trans R Soc Trop Med Hyg 1985, 79:419-420.
7. Harrison V.R., Binn L.N., Randall R. Comparative immunogenicities of chikungunya vaccines prepared in avian a mammalian tissues. Am J Trop Med Hyg 1967, 16:786-791.
8. Harrison V.R., Eckels K.H., Bartelloni P.J., Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J Immunol 1971, 107:643-647.
9. Levitt N.H., Ramsburg H.H., Hasty S.E., Repik P.M., Cole F.E., Lupton H.W. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986, 4:157-162.
10. Widmer J. The spirit of Swiftwater 1998, University of Scranton Press, Scranton PA, p. 64.
11. Recommendations with accompanying analysis of limitations imposed by current department of defense structure for managing acquisition of vaccines against infectious diseases. In: Lemon SM, Thaul S, Fisseha S, O'Maonaigh HC, editors. Protecting our forces. Washington, DC: The National Academies Press; 2002. p. 88, 90-3.
12. Malinoski F.J., Ksiazek T., Ramsburg H., Lupton H.W., Meadors G.F. Safety and immunogenicity of a new chikungunya virus vaccine: double-blind, placebo-controlled human trial. 38th annual meeting of the Amer. Soc. Trop. Med. Hyg. 1989, [section 8.2].
13. Edelman R., Tacket C.O., Wasserman S.S., Bodison S.A., Perry J.G., Mangiafico J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000, 62:681-685.
14. Borgherini G., Poubeau P., Staikowsky F., Lory M., Le Moullec N., Becquart J.P., et al. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. CID 2007, 44:1401-1407.
15. Renault P., Solet J.L., Sissoko D., Balleydier E., Larrieu S., Filleul L., et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 2007, 77:727-731.
16. McClain D.J., Pittman P.R., Ramsburg H.H., Nelson G.O., Rossi C.A., Mangiafico J.A., et al. Immunologic interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 1998, 177:634-641.
17. Turell M.J., Malinoski F.J. Limited potential for mosquito transmission of a live, attenuated chikungunya virus vaccine. Am J Trop Med Hyg 1992, 47:98-103.
18. Chikungunya virus strain AF15561, complete genome. GenBank accession number [accessed 25.05.12]. http://www.ncbi.nlm.nih.gov/nuccore/EF452493.
19. Chikungunya virus strain TSI-GSD-218, complete genome. GenBank accession number [accessed 25.05.12]. http://www.ncbi.nlm.nih.gov/nuccore/L37661.3.
20. Chikungunya virus strain TSI-GSD-218-VR1, complete genome. GenBank accession number [accessed 25.05.12]. http://www.ncbi.nlm.nih.gov/nuccore/EF452494.1.
21. Staples J.E., Breiman R.F., Powers A.M. Chikungunya fever: an epidemiological review of a re-emerging infectious disease. Clin Infect Dis 2009, 49:942-948.
22. Charrel R.N., de Lamballerie X., Raoult D. Chikungunya outbreaks - the globalization of vectorborne diseases. N Engl J Med 2007, 356:769-771.
23. Gorchakov R., Wang E., Leal G., Forrester N.L., Plante K., Rossi S.L., et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the e2 envelope glycoprotein. J Virol 2012, 86:6084-6096.
24. Tsetsarkin K.A., Vanlandingham D.L., McGee C.E., Higgs S. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007, 3:e201.
25. Burnette W.N., Hoke C.H., Scovill J., Clark K., Abrams J., Kitchen L.W., et al. Infectious diseases investment decision evaluation algorithm: a quantitative algorithm for prioritization of naturally occurring infectious disease threats to the U.S. military. Mil Med 2008, 173(February (2)):174-181.
26. Update: chikungunya fever diagnosed among international travelers - United States, 2006. MMWR Morb Mortal Wkly Rep 2007, 56:276-277. Centers for Disease Control and Prevention (CDC).
27. [accessed 11.05.12]. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/yellow-fever-and-malaria-information-by-country/costarica.htm.
28. Plante K., Wang E., Partidos C.D., Weger J., Gorchakov R., Tsetsarkin K., et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog 2011, 7:e1002142.
29. Darwin J.R., Kenney J.L., Weaver S.C. Transmission potential of two chimeric Chikungunya vaccine candidates in the urban mosquito vectors, Aedes aegypti and Ae. albopictus. Am J Trop Med Hyg 2011, 84:1012-1015.
30. Wang D., Suhrbier A., Penn-Nicholson A., Woraratanadharm J., Gardner J., Luo M., et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011, 29:2803-2809.
31. Mallilankaraman K., Shedlock D.J., Bao H., Kawalekar O.U., Fagone P., Ramanathan A.A., et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011, 11(5):e928.
32. Partidos C.D., Weger J., Brewoo J., Seymour R., Borland E.M., Ledermann J.P., et al. Probing attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 2011, 29:3067-3073.
33. Eckels K.H., Harrison V.R., Hetrick F.M. Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol 1970, 19:321-325.
34. Tiwari M., Parida M., Santhosh S.R., Khan M., Dash P.K., Rao P.V. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27:2513-2522.
35. Hepatitis A vaccine package insert: see section 11. [accessed 22.05.12]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM224555.pdf.
36. Japanese encephalitis vaccine package insert: see section 11. [accessed 22.05.12]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM142569.pdf.
37. [accessed 20.04.12]. http://en.wikipedia.org/wiki/Joint_Capabilities_Integration_Development_System.
38. Poletti P., Messeri G., Ajelli M., Vallorani R., Rizzo C., Merler S. Transmission potential of chikungunya virus and control measures: the case of Italy. PLoS One 2011, 6:e18860.
39. Hoke C.H., Hawksworth A., Snyder C.E. Initial assessment of impact of adenovirus type 4 and type 7 vaccine on febrile respiratory illness and virus transmission in military basic trainees, March 2012. MSMR 2012, 19:2-4.